Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
April 06, 2022 08:00 ET
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
March 30, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
March 25, 2022 08:00 ET
|
Morphic Therapeutic
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM,...
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
March 04, 2022 09:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
February 24, 2022 07:30 ET
|
Morphic Therapeutic
Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at...
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
February 22, 2022 08:00 ET
|
Morphic Therapeutic
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 ...
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Participation in Upcoming Investor Conferences
November 16, 2021 09:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
November 15, 2021 09:05 ET
|
Morphic Therapeutic
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...
Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Morphic Therapeutic
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D.,...